Pfizer in cancer vaccine pact with Avant

Avant Immunotherapeutics stands to receive at least $50 million from an agreement with Pfizer for the development of CDX-110, an experimental brain cancer vaccine. The drugmakers plan to test CDX-110 -- acquired by Avant after finalizing a merger with Celldex Therapeutics -- for other cancers, including breast, ovarian, advanced prostate and colorectal cancer.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT